Generic Name: ivosidenib

Pronunciation: N/A

Abbreviation: N/A

Other Market Name: N/A

Drug Class: Targeted Therapy Medications

Company: Agios

Approval Status: Approved

Generic Version Available: No

Experimental Code: N/A


Drug Recommendation

Tibsovo is an IDH1 inhibitor approved for adults with acute myeloid leukemia with IDH1 mutations that has relapsed or does not respond to prior treatment.


General Info

Tibsovo inhibits isocitrate dehydrogenase-1, an enzyme that plays a role in cellular metabolism. The drug targets mutant versions of the enzyme produced by cancerous blood cells. A study showed that 33 percent of treated patients achieved complete remission with full or partial normalization of blood cell counts. A third went nearly two months without needing a blood transfusion. Tibsovo was approved on July 20, 2018.


Dosage

Dosing Info:

Tibsovo is a tablet taken once daily with or without food until disease progression or unacceptable side effects occur.


Side Effects

Common side effects include fatigue, joint pain, diarrhea, nausea, swelling, mouth sores, skin rash, constipation and elevated white blood cell count. Potential serious side effects may include irregular heart rhythm and a neurological disorder known as Guillain-Barré syndrome. The Tibsovo label has a warning about differentiation syndrome, a set of symptoms including swelling and shortness of breath that can occur when myeloid cells mature. Tibsovo should not during pregnancy or breastfeeding.


For More Info: https://www.tibsovo.com/

Patient Assistance Program Info: https://www.myagios.com/patient/index.html

Last Reviewed: December 3, 2018